Hob Biotech Group Corp., Ltd. Class ASSE: 688656

Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New Business

· Issued by Hob Biotech Group Corp., Ltd. Class A via Shanghai Stock Exchange
Announcement on Progress in Voluntary Disclosure of Phase III Clinical Trial of MM09 Sublingual Spray for Allergy Immunotherapy Completes Enrollment of First Subjects Along with New Business

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis